Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A Nephropathy

Interventions

DRUG: Sibeprenlimab 400 mg
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.